<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26882102</PMID><DateCompleted><Year>2016</Year><Month>08</Month><Day>01</Day></DateCompleted><DateRevised><Year>2019</Year><Month>02</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>2</Issue><PubDate><Year>2016</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Clinical Efficacy of Therapy with Recombinant Human Interferon &#x3b1;1b in Hand, Foot, and Mouth Disease with Enterovirus 71 Infection.</ArticleTitle><Pagination><StartPage>e0148907</StartPage><MedlinePgn>e0148907</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0148907</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0148907</ELocationID><Abstract><AbstractText Label="UNLABELLED">A rapid expansion of HFMD with enterovirus 71 infection outbreaks has occurred and caused deaths in recent years in China, but no vaccine or antiviral drug is currently available for EV71 infection. This study aims to provide treatment programs for HFMD patients. We conducted a randomized, double-blind, controlled trial and evaluated clinical efficacy of therapy with rHuIFN-&#x3b1;1b in HFMD patients with EV71 infection. There were statistical differences in outcomes including the fever clearance time, healing time of typical skin or oral mucosa lesions, and EV71 viral load of the HFMD patients among ultrasonic aerosol inhalation group, intramuscular injection group and control group. rHuIFN-&#x3b1;1b therapy reduced the fever clearance time, healing time of typical skin or oral mucosa lesions, and EV71 viral load in children with HFMD.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">Chinese Clinical Trial Registry ChiCTR-TRC-14005153.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Xueyong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Henan Center for Disease Control and Prevention, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Children's Hospital of Kaifeng City, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Fang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Children's Hospital of Zhengzhou City, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Haiyan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Henan Center for Disease Control and Prevention, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Henan Center for Disease Control and Prevention, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sui</LastName><ForeName>Meili</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>College of Public Health, Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>College of Public Health, Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Huaili</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dumler</LastName><ForeName>J Stephen</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Departments of Pathology and Microbiology &amp; Immunology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheng</LastName><ForeName>Guangyao</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Bianli</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Henan Center for Disease Control and Prevention, Zhengzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ChiCTR</DataBankName><AccessionNumberList><AccessionNumber>CHICTR-TRC-14005153</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>02</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>2</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>2</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26882102</ArticleId><ArticleId IdType="pmc">PMC4755579</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0148907</ArticleId><ArticleId IdType="pii">PONE-D-15-37784</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Xu M, Su L, Cao L, Zhong H, Dong N, Xu J. Enterovirus genotypes causing hand foot and mouth disease in Shanghai, China: a molecular epidemiological analysis. BMC Infect Dis. 2013;13: 489 10.1186/1471-2334-13-489</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2334-13-489</ArticleId><ArticleId IdType="pmc">PMC4015791</ArticleId><ArticleId IdType="pubmed">24148902</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan X, Huang X, Zhu S, Chen H, Yu Q, Wang H, et al. The persistent circulation of enterovirus 71 in People's Republic of China: causing emerging nationwide epidemics since 2008. PLoS One. 2011; 6(9): e25662 10.1371/journal.pone.0025662</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0025662</ArticleId><ArticleId IdType="pmc">PMC3181342</ArticleId><ArticleId IdType="pubmed">21980521</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X, Wei H, Wu S, Du Y, Liu L, Su J, et al. Epidemiological and etiological characteristics of hand, foot, and mouth disease in Henan, China, 2008&#x2013;2013. Sci Rep. 2015;5:8904 10.1038/srep08904</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep08904</ArticleId><ArticleId IdType="pmc">PMC4354091</ArticleId><ArticleId IdType="pubmed">25754970</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadurugamuwa JL, Shaheen E. Inactivation of human enterovirus 71 and coxsackie virus A16 and hand, foot, and mouth disease. Am J Infect Control. 2011;39(9):788&#x2013;789. 10.1016/j.ajic.2011.01.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajic.2011.01.015</ArticleId><ArticleId IdType="pubmed">21565426</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Tan X, Cui A, Mao N, Xu S, Zhu Z, et al. Complete genome analysis of the C4 subgenotype strains of enterovirus 71: predominant recombination C4 viruses persistently circulating in China for 14 years. PLoS One. 2013; 8(2):e56341 10.1371/journal.pone.0056341</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0056341</ArticleId><ArticleId IdType="pmc">PMC3575343</ArticleId><ArticleId IdType="pubmed">23441179</ArticleId></ArticleIdList></Reference><Reference><Citation>Tee KK, Lam TT, Chan YF, Bible JM, Kamarulzaman A, Tong CY, et al. Evolutionary genetics of human enterovirus 71: origin, population dynamics, natural selection, and seasonal periodicity of the VP1 gene. J Virol. 2010;84(7):3339&#x2013;3350. 10.1128/JVI.01019-09</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01019-09</ArticleId><ArticleId IdType="pmc">PMC2838098</ArticleId><ArticleId IdType="pubmed">20089660</ArticleId></ArticleIdList></Reference><Reference><Citation>Urin V, Levin D, Sharma N, Harari D, Schreiber G. Fine Tuning of a Type 1 Interferon Antagonist. PLoS One. 2015;10(7):e0130797 10.1371/journal.pone.0130797</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0130797</ArticleId><ArticleId IdType="pmc">PMC4497658</ArticleId><ArticleId IdType="pubmed">26158644</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannidis I, Ye F, McNally B, Willette M, Flano E. Toll-like receptor expression and induction of type I and type III interferons in primary airway epithelial cells. J Virol. 2013;87(6):3261&#x2013;3270. 10.1128/JVI.01956-12</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01956-12</ArticleId><ArticleId IdType="pmc">PMC3592129</ArticleId><ArticleId IdType="pubmed">23302870</ArticleId></ArticleIdList></Reference><Reference><Citation>Masci P, Olencki T, Wood L, Rybicki L, Jacobs B, Williams B, et al. Gene modulatory effects, pharmacokinetics, and clinical tolerance of interferon-alpha1b: a second member of the interferon-alpha family. Clin Pharmacol Ther. 2007;81(3):354&#x2013;361.</Citation><ArticleIdList><ArticleId IdType="pubmed">17339865</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Y, Zhao L, Wu T, Guo S, Chen Y, Zhou T. Efficacy of consensus interferon in treatment of HbeAg-positive chronic hepatitis B: a multicentre, randomized controlled trial. Virol J. 2009;6:99 10.1186/1743-422X-6-99</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-6-99</ArticleId><ArticleId IdType="pmc">PMC2715390</ArticleId><ArticleId IdType="pubmed">19586556</ArticleId></ArticleIdList></Reference><Reference><Citation>Stegmann KA, Bj&#xf6;rkstr&#xf6;m NK, Ciesek S, Lunemann S, Jaroszewicz J, Wiegand J, et al. Interferon &#x3b1;-stimulated natural killer cells from patients with acute hepatitis C virus (HCV) infection recognize HCV-infected and uninfected hepatoma cells via DNAX accessory molecule-1. J Infect Dis. 2012;205(9):1351&#x2013;1362. 10.1093/infdis/jis210</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jis210</ArticleId><ArticleId IdType="pmc">PMC3690562</ArticleId><ArticleId IdType="pubmed">22457290</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun W, Yang L, Jia YY, Qiao Y, Wen AD. Tolerance and Safety Study of Aerosol Inhalation of Recombinant Human Interferon &#x3b1;1b in Children with Viral Pneumonia. China Pharmacy. 2011;22(14): 1277&#x2013;1280.</Citation></Reference><Reference><Citation>Liu X, Lu J, He ML, Li Z, Zhang B, Zhou LH, et al. Antitumor effects of interferon-alpha on cell growth and metastasis in human nasopharyngeal carcinoma. Curr Cancer Drug Targets. 2012;12(5):561&#x2013;570.</Citation><ArticleIdList><ArticleId IdType="pubmed">22414012</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang XY, Kang K, Xu YL, Wei HY, Li XL, Ma H, et al. Etiology surveillance of hand-foot-mouth disease in Henan province between 2008 and 2011. Chin J Prev Med. 2012;46(10):883&#x2013;887.</Citation><ArticleIdList><ArticleId IdType="pubmed">23363860</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu HJ, Xu BL, Huang XY, Wei HY, Li XL, Du YH. Construction and primary application on a TaqMan PCR detection method for detection of enterovirus 71. Modern Preventive Medicine. 2010; 37(8): 1517&#x2013;1523.</Citation></Reference><Reference><Citation>Ding X, Nie K, Shi L, Zhang Y, Guan L, Zhang D, et al. Improved detection limit in rapid detection of human enterovirus 71 and coxsackievirus A16 by a novel reverse transcription-isothermal multiple-self-matching-initiated amplification assay. J Clin Microbiol. 2014;52(6):1862&#x2013;1870. 10.1128/JCM.03298-13</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.03298-13</ArticleId><ArticleId IdType="pmc">PMC4042787</ArticleId><ArticleId IdType="pubmed">24648558</ArticleId></ArticleIdList></Reference><Reference><Citation>Bible JM, Pantelidis P, Chan PK, Tong CY. Genetic evolution of enterovirus 71: epidemiological and pathological implications. Rev Med Virol. 2007;17(6):371&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">17487831</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu LJ, Jiang T, Zhang FJ, Han JF, Liu J, Zhao H, et al. Global transcriptomic analysis of human neuroblastoma cells in response to enterovirus type 71 infection. PLoS One. 2013;8(7):e65948 10.1371/journal.pone.0065948</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0065948</ArticleId><ArticleId IdType="pmc">PMC3702535</ArticleId><ArticleId IdType="pubmed">23861741</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao HJ, Liu ZL, Steinmann P, Mu YJ, Luo H, Liu JP. Chinese herbal medicines for treatment of hand, foot and mouth disease: A systematic review of randomized clinical trials. European Journal of Integrative Medicine. 2012; 4: 85&#x2013;111.</Citation></Reference><Reference><Citation>Ryu WS, Kang B, Hong J, Hwang S, Kim J, Cheon DS. Clinical and etiological characteristics of enterovirus 71-related diseases during a recent 2-year period in Korea. J Clin Microbiol. 2010;48(7):2490&#x2013;2494. 10.1128/JCM.02369-09</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.02369-09</ArticleId><ArticleId IdType="pmc">PMC2897491</ArticleId><ArticleId IdType="pubmed">20463159</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>